We have investigated the significance of telomerase activity (TA) and telomere length (TL) in multiple myeloma (MM). The analyses were undertaken on CD138 + MM cells isolated from the marrow of 183 patients either at diagnosis or in relapse. There was heterogeneity in telomerase expression with 36% having TA comparable to the activity detected in normal plasma cells and 13% having levels 1-4 fold greater than in a neuroblastoma cell line control. The TL of MM cells was significantly shorter than that of the patients' own leukocytes, with 25% of cases having a TL of <4.0kbp. Analysis of TL distribution indicated selective TA-mediated stabilization of shorter telomeres when mean TL fell below 5.5kbp. Unusually long telomeres were observed in seven cases (10.8-15.0 kbp) with low TA in 5/7, suggesting the operation of a TA-independent pathway of telomere stabilization. There was a strong negative correlation between TA and TL or platelet count. TL negatively correlated with age and with IL-6 and 2-microglobulin levels. Various cytogenetic abnormalities, including those associated with poor prognosis, strongly correlated with TA and to a lesser extent with short TL. High TA and short TL defined a subgroup of patients with poor prognosis. At one year there was an 82% survival in patients with TA of <25% of neuroblastoma control and a TL of >5.5 kbp versus a 63% survival in patients with higher TA and shorter TL (P=.004). The two-year survival of patients with a TA of <25% was 81% versus 52% in those with a higher TA (P<.0001).
Introduction
As normal cells undergo repeated rounds of DNA replication, their telomeres shorten due to the inability of traditional DNA polymerases to completely replicate the end of the chromosomal DNA. 1 This shortening continues until the cells reach a proliferative block referred to as crisis, which is characterized by chromosomal instability, end-to-end fusions, and cell death. Stabilization of the telomeric DNA through either telomerase activation or the activation of the alternative mechanism of telomere maintenance (ALT) is essential if the cells are to survive and proliferate indefinitely. [2] [3] [4] In ~85% of all human cancer, immortalization is associated with upregulation of telomerase. Direct evidence for the role of telomerase in cancer has been obtained in studies in which normal human lung or breast epithelium, 5, 6 or marrow endothelium 7 are transfected with the catalytic subunit of telomerase, hTERT, together with the Simian Virus 40 large T antigen and ras oncogenes. This is sufficient to confer immortality and malignant behavior in vivo. Conversely, loss of telomere stabilization by an alreadyimmortalized cell, for example following telomerase inhibition, results in loss of immortality and cell death. 1, [8] [9] [10] Together, these studies indicate that telomere maintenance is a critical component of cancer cell immortality.
The significance of telomerase expression in human malignancy has been evaluated extensively in solid tumors, [11] [12] [13] [14] [15] [16] [17] [18] hematopoietic malignancies, [19] [20] [21] and on a smaller scale, in lymphoid malignancies. [22] [23] [24] [25] [26] [27] [28] The number of studies where tumor telomere length (TL) was evaluated in parallel with telomerase has been more limited, and while in some solid tumors the concept that high telomerase levels lead to tumor telomere elongation has been supported, it is by no means clear if this simple relationship is generally applicable-particularly in view of the increasing understanding of the complexity of molecular interactions at the chromosome ends. In B cell malignancies such as non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and hairy cell leukemia elevated telomerase levels were reported relative to normal B lymphocytes, however benign germinal center B cells also showed high levels of telomerase activity (TA). 22, 24 This has led to the suggestion that telomerase expression in malignant B cells can be explained by an "induction and retention" model of reactivation of telomerase in malignant clones. 22 In B-CLL a high inverse correlation was noted between TL and TA and patients in early stage disease had significantly longer telomeres than at late stage. 22 Short
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From telomeres and high TA were significantly associated with shorter mean survival. In multiple myeloma (MM), two small studies on TA, but not TL, have been reported. In one, telomerase was not elevated in plasma cells (PCs) from five patients with monoclonal gammopathy of undetermined significance (MGUS) but was elevated in 21/27 patients with MM and in all four cases of plasma cell leukemia. 27 In another study of 25 patients with MM, elevated TA correlated with high 2 -microglobulin ( 2 M) levels, clinical stage III and shorter survival. 28 The need for more extensive analysis of MM is due to its heterogeneity and what has been described as its "genetic chaos" as reflected in its marked aneuploidy, and the difficulty in establishing correlations between genetic abnormalities and clinical outcome. 29 
Materials and Methods

Patients
All samples were collected from Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences. Table 1 shows the patients' characteristics. Written informed consent was obtained from each patient and donor.
Cell preparations
Marrow PCs were collected from 183 either newly diagnosed or relapsing cases of MM and seven normal donors (normal PCs) after receiving informed consent according to University IRB guidelines. Patient in relapse was defined as recurrence of monoclonal protein or bone marrow plasmacytosis or evidence of extramedullary disease in the case of complete remission (CR) or near CR or any new disease manifestation, including hypercalcemia. Disease progression for non-CR patients implied at least a 25% increase in tumor mass or any new disease manifestation.
PCs isolation from marrow mononuclear cell fraction was performed by immunomagnetic bead selection with monoclonal mouse anti-human CD138 antibody using the AutoMACS separation system (Miltenyi-Biotec, Auburn, CA). PC purity of at least 95% homogeneity was confirmed by two-color flow cytometry using CD138 an enzyme-linked polyclonal antibody specific for IL-6 was added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution was added to the wells with color developing in proportion to the amount of IL-6 bound in the initial step. The color development was stopped and the intensity of the color was measured.
Plasma cell labelling index assay
A specimen of aspirate of bone marrow or of a tumor was processed to isolate the mononuclear cells. These cells were then stained for cytoplasmic light chain proteins (kappa or lambda) and a BUdR antibody to detect all plasma cells in the "S" phase. were compared using the Chi-square test. Survival distributions were presented using the method of Kaplan and Meier 36 and were compared using the log-rank test. 37 Analyses were performed using SAS statistical software.
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Results
Telomerase activity detected in CD138 + PCs from patients with MM and normal donors
To evaluate the telomerase expression in CD138 + cells, TA in enriched MM cells from 183 MM patients and PCs from 7 normal donors was measured (Fig 1-2 , Table 2 ). There was a heterogeneous distribution of TA in the MM samples with a median activity being 8.2% of the neuroblastoma (NB) cell line control (Fig 1-2) . Thirty-six percent of samples had no significant TA, and 64% had TA over 5% of the NB control. Thirteen percent of the total (n=24), had very high TA, between 100-427% of the NB levels. The median TA of MM cells from newly diagnosed patients (n=86) was significantly (P=.001) lower (6.3%) than found with specimens from the 97 relapsed patients who had prior therapy (16.2%). In normal donors, the TA of marrow PCs ranged from 0.3-22.5%, with a median of 3.7% (Table 2 ). All five myeloma cell lines expressing high TA ranged from 87-266% with a median of 180% (Table 2) .
Telomere length in CD138 + MM cells and normal PCs relative to patients' peripheral blood granulocytes and lymphocytes
TL in marrow PCs from 115 MM patients and 7 normal donors was determined by TRF
Southern blot analysis (Fig 3 ; Table 2 Table 2 ). While the mean age of the normal donors was significantly younger than the MM population, when matched with comparable age MM patients the TL in PCs from MM was still significantly shorter than in normal PCs (P<.01) (Fig 3, Table 1 ). In addition, TL was measured in purified peripheral blood granulocytes and lymphocytes from 48 of the 115 cases of MM, allowing us to evaluate the TL alterations in different cell types from the same patient. The results showed that TL was significantly shorter in marrow MM cells than in granulocytes and lymphocytes from the same individual (P<.001). There was no significant difference in TL neither between patients' own granulocytes and lymphocytes nor patients' granulocytes and lymphocytes versus those of donors (Fig. 3 ).
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31, 38 The second concept was based on studies in which hTERT transduction was used to transiently express telomerase in human fibroblasts. 35, 39 In the latter studies, preferential shortening of the longest telomeres was observed, accompanied by a narrowing of the size distribution of all the telomeres, so that the average length becomes much closer to the shortest length than that in the parental cells. Thus when the cells eventually reached senescence the mean TL was 1.5-2.0 kbp shorter than the non-senescent control, while the length of the shortest telomeres at senescence was unchanged. To test the validity of either of these concepts in the MM model, we evaluated the telomere range in the TRF southern blot smear, determining the means of the telomeric DNA either > or < than the overall mean TRF (Fig. 5A ). To establish a non-malignant, TA-negative control we determined these parameters in the patients' granulocyte population. As shown in Fig.   5B and 5C, the shorter and longer mean TRF were constant relative to the overall mean TRF over the range of 5.5-9.5 kbp in both MM cells and granulocytes. However in myeloma cells with mean TRF in the range of 5.5-3.0 kbp, while the shorter telomeres were stable, the contribution of the longer telomeres was significantly reduced as the mean TRF progressively shortened (Fig. 5B) . This was not seen in the granulocytes although the shortest mean TRF was 5.0 kbp (Fig. 5C ).
Correlation of telomerase activity and telomere length with MM clinical and cytogenetic parameters
We explored the correlation of TA and TL in MM cells with clinical parameters (Table   3 ). In addition to the strong negative correlation between TA and TL (P=<.001), there was a strong positive correlation between age and TA (P=.002), with a weaker negative correlation with TL (P=.034). There was no significant influence of ethnicity on either TA or TL. (Fig. 6B ). In the newly diagnosed group we still observed a trend to poorer survival in patients with higher TA than in lower TA but this did not reach statistical significance (P=0.08, Fig. 6C ), most likely due to the small number of patients in this group. Dividing the diagnosed or relapsed patients into those with a TL<, versus the median of 5.5 kbp did not reveal any significant difference in survival rate (data not shown).
Discussion
The current study demonstrated that TA negatively correlated with TL, and strongly correlated with MM patients' two-year survival although there was a heterogeneous distribution level. There was a strong negative correlation of IL-6 level and telomere length (P=.008). TA was strongly correlated with age (P=.002) which is in contrast to results in large studies of primary lung cancer 16 and breast cancer 18 where a negative correlation with age was observed.
There was a significant positive correlation of TA and a negative correlation of TL with poor prognosis features such as 2-M levels 43 and chromosome 13 deletions. 44 However our analysis showed that TA, but not TL, is strongly predictive of one and two-year survival. The observation that low platelet count at diagnosis correlated with high TA and low TL could not be explained by replacement of marrow hematopoiesis by infiltrating MM cells since there was no significant correlation with hemoglobin levels, neutrophil or white blood cell counts, or with percentage of PCs in the marrow.
The data showing a strong correlation between short telomeres and high TA in MM cells can be used to support the concept of protection of critically shortened telomeric DNA by telomerase "capping". 31, 37 However, our analysis of telomeric DNA distribution in myeloma cells showed preferential stabilization of shorter telomeres with progressive erosion of longer telomeres, particularly in the cases where mean TRF fell below 5.5 kbp. Nevertheless, the data supports the concept of preferential telomerase stabilization of short telomeres as their length becomes a critical trigger for initiation of cell death/senescence induced by either the p53 or the p16-RB pathways. 35, 39 A further mechanism that has been evoked to explain short telomeres in Our identification of a small group of patients (7/115) whose tumor cells have excessively long telomeres (10.8-15.0 kbp) is particularly significant in view of the particularly short mean TL that characterizes the majority of cases (Table 2 ). This group may utilize a nontelomerase mechanism for telomere maintenance (ALT), involving inter-telomeric homologous recombination. 49 ALT is reported in ~5% of tumor, mostly carcinoma-derived cell lines. 49 Since 2/7 of our candidate ALT cases had elevated telomerase levels, we propose that ALT may, in some cases co-exist with telomerase-induced telomere stabilization, as previously shown in immortalized W138 cells. 50 The existence of an ALT pathway in normal B cell development has been documented in mice that have lost TA due to a knockout mutation (mTR-/-).associated promyelocytic leukemia (PML) bodies have been reported as large donut shaped nuclear structures containing PML protein, telomeric DNA and TRF-1 and TRF-2. 52 We are currently evaluating our myeloma population, both prospectively and retrospectively, for such PML bodies and their association with particularly long telomeres.
Myeloma is associated with considerable cytogenetic instability involving translocations and additions or deletions of whole chromosomes. We observed a very strong correlation between any cytogenetic abnormality, as well as any whole chromosome addition or deletion, and the co-existence of high TA and short TL (Table 4 ). Of 13 specific chromosome abnormalities that correlated strongly with high TA, seven also correlated with short TL.
Deletion of chromosome 13 was associated with both high TA and short TL. Cytogenetic analysis has shown partial or complete deletion of chromosome 13 in 15-20% of MM patients at diagnosis and this imparts a poor prognosis suggestive of a tumor suppressor gene(s) on this chromosome. 44 We observed a very strong correlation between high telomerase, short telomeres and a cytogenetic profile in the myeloma cells that has been associated with MDS. In a cytogenetic study of 868 patients with myeloma, abnormalities typical of MDS (e.g. 5q-, -5, 7q-, -7, t (1; 7), +8, 20q-) were found either as sole abnormalities in individual metaphases in 5% of cases, or associated with abnormalities characteristic of myeloma within the same metaphases in 10% of cases. 53 In six patients whose myeloma cells showed MDS cytogenetic abnormalities, MDS independently developed. The evolution of these specific cytogenetic abnormalities may be due to a common mechanism operating in malignant myeloid and lymphoid cells that could be directly linked to telomere shortening. Genetic instability associated with gross cytogenetic change is observed in many cancers and points to the role of shortened telomeres leading to chromosome fusion and formation of dicentric structures that are resolved by fragmentation or unequal distribution to daughter cells with repeated cycles of breakage-fusion-bridge formation probably coupled with the capacity to survive such changes e.g. by loss of p53. 54 Such cytogenetic instability is seen in cells with short telomeres, for example in late generation telomerase null mice (mTR-/-). 55 We observed a highly significant correlation between chromosome 3 duplication and high TA with short telomeres ( 59 The absence of a telomerase suppressor effect associated with chromosome 3 duplication in myeloma may be related to a tissue-specific suppressor activity since suppression was reported in tumors of the kidney and breast where TA is strongly suppressed in the normal tissues of these organs, versus myeloma as a malignancy in the B cell compartment where telomerase is strongly expressed in the course of normal development.
We observed a strong correlation between TA and frequency of "jumping" 1q arm abnormality in myeloma cells. This abnormality has been reported in up to 23% of myeloma patients with abnormal karyotype and was speculated to involve de-condensation of pericentric heterochromatin. 60 In MDS with jumping 1q21, the region distal to 1q21 jumps onto numerous different telomeres, leading to the suggestion that critical telomere shortening can trigger the "jump". 61 We did not observe a significant correlation between telomere shortening and this abnormality, favoring the decondensation model.
In conclusion, these studies have provided insight into the role of telomerase in cancer. It has indicated two mechanisms for achieving myeloma cell immortality (TA stabilization of short telomeres and ALT), and has supported a link between cytogenetic instability and TL. In addition TA has proven to be predictive of MM patient prognosis as determined by two-year survival. The identification of over 25% of cases with a TL of <4.0 kbp indicates that MM should be highly amenable to anti-telomerase therapy since rapid onset of senescence or apoptosis would be expected due to limited amount of telomeric DNA on certain chromosome ends. Monoclonal CD138 antibody was used to isolate myeloma cells with a purity of over 95% from bone marrow of patients with active disease. The results were expressed as a percentage of activity in a neuroblastoma (NB) cell line standard. The results showed that TA ranged from 0 -427% of the activity in a NB cell line standard, and about 36% of myeloma cases had TA of <5%, 51% had TA of 5-100%, and 13% had greater activity than this highly telomerase-positive tumor (>100%). Telomerase Activity (% of NB) There was no significant difference in TL between patients' own granulocytes and lymphocytes or patients' granulocytes and lymphocytes versus those of donors. (Fig. 5B) , and the patients' own granulocytes showed a similar relationship (Fig. 5C) . A progressive shortening of the longest telomeres was seen in MM cells when mean TRF fell from 5.5 to 3.0 kbp, with stabilization of the shortest telomeres (Fig. 5B) .
Legends for Figures
This was not seen in the granulocytes although the shortest mean TRF was 5.0 kbp (Fig. 5C ).
The lines showed in Fig. 5B and 5C were y=x reference line. 
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For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Figure 6 . Overall survival by telomerase activity in patients with multiple myeloma. When TA is <25% of NB cell control, the estimated patient two-year overall survival was 81%, and when TA was 25% of NB cell control, the estimated patient two-year overall survival was 52% (Fig. 6A, P<.0001) . When divided into newly diagnosed and relapsed groups, the relapsed patients whose MM cells had a TA of 25% the activity of NB control had a significantly shorter survival than those patients with lower levels of TA (P=.01, Fig. 6B ). In the newly diagnosed group there was a trend to poorer survival in patients with higher TA than in lower TA but this did not reach statistical significance (P=.08, Fig. 6C ). Numbers in parentheses represent 95% confidence interval.
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